Clinical Read2026-06-30
Tildacerfont
Spruce BiosciencesSPRB
- Indication
- Major Depressive Disorder (MDD)
- Stage
- Phase 2
- Event
- Phase 2 Data readout
- Details
TAMARIND trial. 7/22/25- First patient dosed. 8/14/25- Topline results in H1 2026. 11/10/25:- PR No update. 03/09/26:- PR No update. 05/13/26:- PR No update.
Financial Snapshot
Market Cap
$129.7M
Price
$49.11